Average Insider

Where insiders trade, we follow

$XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Healthcare
Sector
Medical - Diagnostics & Research
Industry
John Aballi
CEO
209
Employees
$4.13
Current Price
$143.68M
Market Cap
52W Low$2.59
Current$4.1323.0% above low, 77.0% below high
52W High$9.28

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys12$410,244.5578,4001:1.82
Sells12$745,794.84167,504
2 weeksBuys13$464,219.5586,9001:1.76
Sells13$814,961.94178,769
1 monthBuys14$568,659.55100,9001:1.43
Sells13$814,961.94178,769
2 monthsBuys14$568,659.55100,9001:1.91
Sells24$1,084,752.84213,063
3 monthsBuys14$568,659.55100,9001:2.17
Sells35$1,233,534.38233,677
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 13, 2026
Chernett Jorey
10% Owner
Sale58,068$4.08$236,917.44View Details
Nov 12, 2026
Chernett Jorey
10% Owner
Sale109,436$4.65$508,877.40View Details
Nov 11, 2026
Chernett Jorey
10% Owner
Purchase71,315$5.23$372,977.45View Details
Nov 10, 2026
Chernett Jorey
10% Owner
Purchase7,085$5.26$37,267.10View Details
Nov 6, 2026
Chernett Jorey
10% Owner
Sale11,265$6.14$69,167.10View Details
Nov 9, 2026
Chernett Jorey
10% Owner
Purchase8,500$6.35$53,975.00View Details
Oct 19, 2026
Chernett Jorey
10% Owner
Purchase14,000$7.46$104,440.00View Details
Oct 16, 2026
ABALLI JOHN
Director
Sale34,294$7.87$269,790.90View Details
Sep 1, 2026
Black Jeffrey G.
Chief Financial Officer
Sale20,614$7.22$148,781.55View Details
3 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 10, 2026
EPS
Estimated-$0.18
Actual-$0.25
Miss
Revenue
Estimated$18.34M
Actual$18.42M
Beat
Nov 3, 2026
EPS
Estimated-$0.19
ActualN/A
Revenue
Estimated$18.34M
ActualN/A
1 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.10.12